The combination therapy of prednisolone and tacrolimus for severe painful bladder syndrome/interstitial cystitis

Authors

  • Gou Kaneko Department of Urology, Kyosai Tachikawa Hospital, Tokyo, Japan; Department of Urology, Keio University School of Medicine, Tokyo, Japan
  • Koshiro Koshiro Department of Urology, Kyosai Tachikawa Hospital, Tokyo, Japan;
  • Yujiro Ito Department of Urology, Kyosai Tachikawa Hospital, Tokyo, Japan; Department of Urology, Keio University School of Medicine, Tokyo, Japan
  • Atsushi Uchida Department of Urology, Kyosai Tachikawa Hospital, Tokyo, Japan

DOI:

https://doi.org/10.5489/cuaj.157

Abstract

A 47-year-old woman visited our hospital with complaints of frequent

urination and intensive pelvic pain. Painful bladder syndrome/

interstitial cystitis (PBS/IC) was suspected based on her

symptoms. Hydrodistention was performed, and crack and petechial

hemorrhage were found, and she was treated with tricyclic

antidepressants and antihistamine. However, these treatments were

ineffective. An allergy or autoimmune reaction was suspected as

the pathogenesis due to eosinophilia and elevation of serum IgE

levels. The patient was then treated with immunosuppressive

agents. Although her symptoms were not sufficiently improved by

single-agent therapy with prednisolone or tacrolimus, they were

completely improved by their combined administration. This is

the first case to report the effectiveness of combination therapy

consisting of prednisolone and tacrolimus to treat PBS/IC.

Downloads

Download data is not yet available.

Author Biographies

Gou Kaneko, Department of Urology, Kyosai Tachikawa Hospital, Tokyo, Japan; Department of Urology, Keio University School of Medicine, Tokyo, Japan

 

 

Department of Urology, Kyosai Tachikawa Hospital, Tokyo, Japan; Department of Urology, Keio University School of Medicine, Tokyo, Japan

Koshiro Koshiro, Department of Urology, Kyosai Tachikawa Hospital, Tokyo, Japan;

Department of Urology, Kyosai Tachikawa Hospital, Tokyo, Japan;

Yujiro Ito, Department of Urology, Kyosai Tachikawa Hospital, Tokyo, Japan; Department of Urology, Keio University School of Medicine, Tokyo, Japan

*

 

Department of Urology, Kyosai Tachikawa Hospital, Tokyo, Japan; Department of Urology, Keio University School of Medicine, Tokyo, Japan

Atsushi Uchida, Department of Urology, Kyosai Tachikawa Hospital, Tokyo, Japan

Department of Urology, Kyosai Tachikawa Hospital, Tokyo, Japan

Downloads

Published

2012-12-17

How to Cite

Kaneko, G., Koshiro, K., Ito, Y., & Uchida, A. (2012). The combination therapy of prednisolone and tacrolimus for severe painful bladder syndrome/interstitial cystitis. Canadian Urological Association Journal, 6(2). https://doi.org/10.5489/cuaj.157

Issue

Vol. 6 No. 2 (2012): CUAJ April

Section

Case Report

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.